LEXX News & Events

Lexaria Bioscience (LEXX) is pleased to recognize that the US Food and Drug Administration has approved Eli Lilly and Company's (LLY) Foundayo glucagon-like peptide-1 agonist oral tablet for adult use in controlling obesity and weight-related medical conditions. "This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs," said Richard Christopher, CEO. "Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH technology to improve patient experiences including through the potential for reduced side effects."

Lexaria Bioscience announced the engagement of the contract research organization to execute and report on its Human Pilot Study #7 that will evaluate 2 oral DehydraTECH-semaglutide compositions against commercially available Wegovy tablets. Contracts with the CRO have been signed and submissions are currently being prepared to obtain the required ethics approval from an independent review board. Study design is virtually complete and is expected to be a 5-week parallel group design, investigating 3 separate arms to assess safety & tolerability and pharmacokinetic properties that will compare salcaprozate sodium-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy tablets, under fasted pre-dose conditions. Lexaria hopes to preserve the superior safety & tolerability profiles as evidenced in previous Lexaria GLP-1 studies such as GLP-1-H25-4, combined with PK performance that matches or exceeds that of the commercial oral tablet brands Ryblesus and Wegovy. If successful, the Study results will be additive to a data set aimed at generating interest from pharmaceutical partners seeking to enter into commercial relationships encompassing Lexaria's proprietary DehydraTECH technology.

Lexaria Bioscience provided an update on additional new intellectual property granted to the Company as a result of its ongoing research and development programs. This new IP is recognized with the awarding of 5 new patents. In Lexaria's patent Family #21, Compositions and Methods for Treating Hypertension, the company received 2 new patents in Japan, both issued on February 20, 2026 with a term ending on April 25, 2043. Prior to this, Lexaria already had 3 US and 1 European granted patents in this same family. In patent Family #24, Compositions and Methods for Treating Epilepsy, the company have received 1 new Australian patent issued on February 12, 2026 with a term ending on February 20, 2044. Prior to this, Lexaria already had 6 US; 1 European Union; and 4 previous Australian patents in this patent Family #24. Finally, in patent Family #27, Compositions and Methods for Treating Diabetes, the company received 2 new Australian patents issued on February 12, 2026 with a term ending on December 3, 2044. Prior to this, Lexaria had 2 granted US patents in this newest of patent families.